Beam Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 448.21K shares, a 271.99% increase year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 197.67K shares, a 164.60% increase year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 124.53K shares, a 64.16% decline year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 18.04K shares, a 42.20% decline year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 337.77K shares, a 40.04% decline from fiscal 2024.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 563.35K shares, a 29.38% decline from fiscal 2023.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 797.71K shares, a 64.67% increase from fiscal 2022.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 484.44K shares, a 50.30% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 448.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 788.45K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 197.67K shares 10-Q · filed 2026-05-07 | 460.73K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 124.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 337.77K shares 10-K · filed 2026-02-24 |
| 2025-09-30 | 18.04K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 560.74K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 120.49K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 573.91K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 74.71K shares 10-Q · filed 2025-05-06 | 486.76K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 347.51K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 563.35K shares 10-K · filed 2025-02-25 |
| 2024-09-30 | 31.21K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 408.85K shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 33.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 538.94K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 151.29K shares 10-Q · filed 2024-05-07 | 573.20K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 193.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 797.71K shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 161.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 719.70K shares derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | 67.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 603.89K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 375.81K shares 10-Q · filed 2023-05-10 | 683.59K shares derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | 114.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 484.44K shares 10-K · filed 2023-02-28 |
| 2022-09-30 | 45.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 569.75K shares derived: sum of 4 quarters · filed 2022-11-07 |
| 2022-06-30 | 147.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 693.10K shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 176.65K shares 10-Q · filed 2022-05-09 | 952.03K shares derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | 200.31K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 974.66K shares 10-K · filed 2022-02-28 |
| 2021-09-30 | 168.84K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 1.16M shares derived: sum of 4 quarters · filed 2021-11-08 |
| 2021-06-30 | 406.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | 1.23M shares derived: sum of 4 quarters · filed 2021-08-10 |
| 2021-03-31 | 199.28K shares 10-Q · filed 2021-05-11 | 999.70K shares derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-12-31 | 389.77K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | 859.72K shares 10-K · filed 2021-03-15 |
| 2020-09-30 | 230.14K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | |
| 2020-06-30 | 180.52K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | |
| 2020-03-31 | 59.30K shares 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |